Crystalline form of 1-(8-Bromopyrido[2,3-E][1,2,4]triazolo[4,3-a]pyrazin-4-Yl)-Nmethylazetidin-3-amine hydrogen sulfate monohydrate
AssigneeJw Pharmaceutical Corporation
InventorsSuha Park, Seiho Chin
Life of this patent
Estimating the term…
Abstract
A novel polymorph of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N-methylazetidin-3-amine hydrogen sulfate monohydrate is provided along with pharmaceutical compositions comprising the same. Also disclosed is the use of the novel polymorph for the treatment of diseases, such as atopic dermatitis (AD), itch, pruritus and various forms of urticaria for example chronic idiopathic urticaria subtypes.
Claims12
Crystalline compound 1-(8-bromopyrido[2,3-e][1,2,4]triazolo [4,3-a]pyrazin-4-yl)-N-methylazetidin-3-amine hydrogen sulfate monohydrate characterized by one or more XRPD reflections at approximately (° 2θ) 8.4;
- 14.7 and 17.0 (±0.2 degrees).
Crystalline compound of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo [4,3-a]pyrazin-4-yl)-N-methylazetidin-3-amine hydrogen sulfate monohydrate characterized by one or more XRPD reflections at approximately (°2θ) 8.4, 11.9, 14.7, 15.1 and 17.0 (±0.2 degrees).
Crystalline compound of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N-methylazetidin-3-amine hydrogen sulfate monohydrate characterized by one or more XRPD reflections at approximately (°2θ) 8.4, 11.9, 14.7, 15.1, 17.0, 23.0 and 24.0 (±0.2 degrees).
Dependencies are inferred from the claim text.